Investor Presentaiton
Health Care
2-2-1. Pharmaceuticals
Trends in net sales
Net sales
(\billion)
500
and operating income
Operating income
(\ billion)
(\billion)
200
409.5
400
419.2
407.2
(2.4) (9.6) (22.7)
412.7
406.0 410.0
160
(37.6)
(53.6)
300
120
THE KAITEKI COMPANY
Trends in royalties
for pharmaceutical technologies
40
40
37.6
76.6
200
69.0 69.0
80
22.7
65.0
59.1 60.0
20
20
100
40
9.6
53.6
0
0
0
FY2010 FY2011 FY2012
FY2013 FY2014 FY2015
Forecasts Plan
FY2011
FY2012 FY2013 FY2014
Forecasts
FY2015
Plan
Long-listed products, etc.
Remicade
Gilenya
Others
New products (Japan)
Operating income
Royalties for pharmaceutical technologies
*Simponi, Telavic, Tenelia, Canaglu, Lexapro, Imusera, Tetrabik
Mitsubishi Chemical Holdings
Invokana (Including from FY2013)
17View entire presentation